JAMA Oncology:奥氮平可减少晚期癌症患者的恶心和呕吐

2020-05-10 Allan MedSci原创

奥氮平是一种精神疾病药物,近期的研究发现,奥氮平也可以减少晚期癌症患者的恶心和呕吐。

奥氮平是一种精神疾病药物,近期的研究发现,奥氮平也可以减少晚期癌症患者的恶心和呕吐。这些结果于5月7日在《JAMA Oncology》上发表。梅奥诊所的医学肿瘤学家Charles Loprinzi博士与阿拉巴马大学Rudolph Navari博士共同完成了这项研究。

Charles Loprinzi博士解释说:“大多数癌症患者对化学疗法会出现恶心和呕吐等不良反应。但是,对晚期癌症患者还存在与化疗无关的恶心和呕吐等严重问题的认识却知之甚少”。

Charles Loprinzi博士和其他合作者对30例晚期癌症患者进行了一项随机、安慰剂对照试验,这些患者近期未接受过化学疗法或放射疗法,但确实有恶心和呕吐等反应。研究人员随机分配患者每天接受低剂量的奥氮平或安慰剂。结果表明,奥氮平组患者的呕吐反应较少,食欲更好。在奥氮平组患者中也未观察到患者报告的不良反应事件。

 

原始出处:

https://www.firstwordpharma.com/node/1722731?tsid=4

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1865832, encodeId=723b1865832a7, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sat Mar 20 14:10:43 CST 2021, time=2021-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1983981, encodeId=0143198398102, content=<a href='/topic/show?id=b53b5984ec1' target=_blank style='color:#2F92EE;'>#晚期癌症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59847, encryptionId=b53b5984ec1, topicName=晚期癌症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ba58436, createdName=马龙, createdTime=Sat Jan 23 05:10:43 CST 2021, time=2021-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1674474, encodeId=c32316e4474e1, content=<a href='/topic/show?id=e8aa13359b1' target=_blank style='color:#2F92EE;'>#Oncology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13359, encryptionId=e8aa13359b1, topicName=Oncology)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb7226973259, createdName=circumcision, createdTime=Sat Nov 28 06:10:43 CST 2020, time=2020-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289676, encodeId=92d512896e6e7, content=<a href='/topic/show?id=cbb8e1356f7' target=_blank style='color:#2F92EE;'>#癌症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71356, encryptionId=cbb8e1356f7, topicName=癌症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ba218, createdName=zgwhgch, createdTime=Tue May 12 02:10:43 CST 2020, time=2020-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1396587, encodeId=9c41139658e81, content=<a href='/topic/show?id=3497528842b' target=_blank style='color:#2F92EE;'>#恶心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52884, encryptionId=3497528842b, topicName=恶心)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Tue May 12 02:10:43 CST 2020, time=2020-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036085, encodeId=d3e31036085a4, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Sun May 10 14:10:43 CST 2020, time=2020-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1038032, encodeId=2daa103803215, content=谢谢梅斯分享这么多精彩信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anti-cancer, createdTime=Sun May 10 14:10:43 CST 2020, time=2020-05-10, status=1, ipAttribution=)]
    2021-03-20 minlingfeng
  2. [GetPortalCommentsPageByObjectIdResponse(id=1865832, encodeId=723b1865832a7, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sat Mar 20 14:10:43 CST 2021, time=2021-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1983981, encodeId=0143198398102, content=<a href='/topic/show?id=b53b5984ec1' target=_blank style='color:#2F92EE;'>#晚期癌症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59847, encryptionId=b53b5984ec1, topicName=晚期癌症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ba58436, createdName=马龙, createdTime=Sat Jan 23 05:10:43 CST 2021, time=2021-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1674474, encodeId=c32316e4474e1, content=<a href='/topic/show?id=e8aa13359b1' target=_blank style='color:#2F92EE;'>#Oncology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13359, encryptionId=e8aa13359b1, topicName=Oncology)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb7226973259, createdName=circumcision, createdTime=Sat Nov 28 06:10:43 CST 2020, time=2020-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289676, encodeId=92d512896e6e7, content=<a href='/topic/show?id=cbb8e1356f7' target=_blank style='color:#2F92EE;'>#癌症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71356, encryptionId=cbb8e1356f7, topicName=癌症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ba218, createdName=zgwhgch, createdTime=Tue May 12 02:10:43 CST 2020, time=2020-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1396587, encodeId=9c41139658e81, content=<a href='/topic/show?id=3497528842b' target=_blank style='color:#2F92EE;'>#恶心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52884, encryptionId=3497528842b, topicName=恶心)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Tue May 12 02:10:43 CST 2020, time=2020-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036085, encodeId=d3e31036085a4, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Sun May 10 14:10:43 CST 2020, time=2020-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1038032, encodeId=2daa103803215, content=谢谢梅斯分享这么多精彩信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anti-cancer, createdTime=Sun May 10 14:10:43 CST 2020, time=2020-05-10, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1865832, encodeId=723b1865832a7, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sat Mar 20 14:10:43 CST 2021, time=2021-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1983981, encodeId=0143198398102, content=<a href='/topic/show?id=b53b5984ec1' target=_blank style='color:#2F92EE;'>#晚期癌症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59847, encryptionId=b53b5984ec1, topicName=晚期癌症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ba58436, createdName=马龙, createdTime=Sat Jan 23 05:10:43 CST 2021, time=2021-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1674474, encodeId=c32316e4474e1, content=<a href='/topic/show?id=e8aa13359b1' target=_blank style='color:#2F92EE;'>#Oncology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13359, encryptionId=e8aa13359b1, topicName=Oncology)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb7226973259, createdName=circumcision, createdTime=Sat Nov 28 06:10:43 CST 2020, time=2020-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289676, encodeId=92d512896e6e7, content=<a href='/topic/show?id=cbb8e1356f7' target=_blank style='color:#2F92EE;'>#癌症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71356, encryptionId=cbb8e1356f7, topicName=癌症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ba218, createdName=zgwhgch, createdTime=Tue May 12 02:10:43 CST 2020, time=2020-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1396587, encodeId=9c41139658e81, content=<a href='/topic/show?id=3497528842b' target=_blank style='color:#2F92EE;'>#恶心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52884, encryptionId=3497528842b, topicName=恶心)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Tue May 12 02:10:43 CST 2020, time=2020-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036085, encodeId=d3e31036085a4, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Sun May 10 14:10:43 CST 2020, time=2020-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1038032, encodeId=2daa103803215, content=谢谢梅斯分享这么多精彩信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anti-cancer, createdTime=Sun May 10 14:10:43 CST 2020, time=2020-05-10, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1865832, encodeId=723b1865832a7, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sat Mar 20 14:10:43 CST 2021, time=2021-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1983981, encodeId=0143198398102, content=<a href='/topic/show?id=b53b5984ec1' target=_blank style='color:#2F92EE;'>#晚期癌症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59847, encryptionId=b53b5984ec1, topicName=晚期癌症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ba58436, createdName=马龙, createdTime=Sat Jan 23 05:10:43 CST 2021, time=2021-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1674474, encodeId=c32316e4474e1, content=<a href='/topic/show?id=e8aa13359b1' target=_blank style='color:#2F92EE;'>#Oncology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13359, encryptionId=e8aa13359b1, topicName=Oncology)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb7226973259, createdName=circumcision, createdTime=Sat Nov 28 06:10:43 CST 2020, time=2020-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289676, encodeId=92d512896e6e7, content=<a href='/topic/show?id=cbb8e1356f7' target=_blank style='color:#2F92EE;'>#癌症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71356, encryptionId=cbb8e1356f7, topicName=癌症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ba218, createdName=zgwhgch, createdTime=Tue May 12 02:10:43 CST 2020, time=2020-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1396587, encodeId=9c41139658e81, content=<a href='/topic/show?id=3497528842b' target=_blank style='color:#2F92EE;'>#恶心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52884, encryptionId=3497528842b, topicName=恶心)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Tue May 12 02:10:43 CST 2020, time=2020-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036085, encodeId=d3e31036085a4, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Sun May 10 14:10:43 CST 2020, time=2020-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1038032, encodeId=2daa103803215, content=谢谢梅斯分享这么多精彩信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anti-cancer, createdTime=Sun May 10 14:10:43 CST 2020, time=2020-05-10, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1865832, encodeId=723b1865832a7, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sat Mar 20 14:10:43 CST 2021, time=2021-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1983981, encodeId=0143198398102, content=<a href='/topic/show?id=b53b5984ec1' target=_blank style='color:#2F92EE;'>#晚期癌症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59847, encryptionId=b53b5984ec1, topicName=晚期癌症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ba58436, createdName=马龙, createdTime=Sat Jan 23 05:10:43 CST 2021, time=2021-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1674474, encodeId=c32316e4474e1, content=<a href='/topic/show?id=e8aa13359b1' target=_blank style='color:#2F92EE;'>#Oncology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13359, encryptionId=e8aa13359b1, topicName=Oncology)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb7226973259, createdName=circumcision, createdTime=Sat Nov 28 06:10:43 CST 2020, time=2020-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289676, encodeId=92d512896e6e7, content=<a href='/topic/show?id=cbb8e1356f7' target=_blank style='color:#2F92EE;'>#癌症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71356, encryptionId=cbb8e1356f7, topicName=癌症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ba218, createdName=zgwhgch, createdTime=Tue May 12 02:10:43 CST 2020, time=2020-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1396587, encodeId=9c41139658e81, content=<a href='/topic/show?id=3497528842b' target=_blank style='color:#2F92EE;'>#恶心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52884, encryptionId=3497528842b, topicName=恶心)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Tue May 12 02:10:43 CST 2020, time=2020-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036085, encodeId=d3e31036085a4, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Sun May 10 14:10:43 CST 2020, time=2020-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1038032, encodeId=2daa103803215, content=谢谢梅斯分享这么多精彩信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anti-cancer, createdTime=Sun May 10 14:10:43 CST 2020, time=2020-05-10, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1865832, encodeId=723b1865832a7, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sat Mar 20 14:10:43 CST 2021, time=2021-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1983981, encodeId=0143198398102, content=<a href='/topic/show?id=b53b5984ec1' target=_blank style='color:#2F92EE;'>#晚期癌症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59847, encryptionId=b53b5984ec1, topicName=晚期癌症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ba58436, createdName=马龙, createdTime=Sat Jan 23 05:10:43 CST 2021, time=2021-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1674474, encodeId=c32316e4474e1, content=<a href='/topic/show?id=e8aa13359b1' target=_blank style='color:#2F92EE;'>#Oncology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13359, encryptionId=e8aa13359b1, topicName=Oncology)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb7226973259, createdName=circumcision, createdTime=Sat Nov 28 06:10:43 CST 2020, time=2020-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289676, encodeId=92d512896e6e7, content=<a href='/topic/show?id=cbb8e1356f7' target=_blank style='color:#2F92EE;'>#癌症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71356, encryptionId=cbb8e1356f7, topicName=癌症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ba218, createdName=zgwhgch, createdTime=Tue May 12 02:10:43 CST 2020, time=2020-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1396587, encodeId=9c41139658e81, content=<a href='/topic/show?id=3497528842b' target=_blank style='color:#2F92EE;'>#恶心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52884, encryptionId=3497528842b, topicName=恶心)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Tue May 12 02:10:43 CST 2020, time=2020-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036085, encodeId=d3e31036085a4, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Sun May 10 14:10:43 CST 2020, time=2020-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1038032, encodeId=2daa103803215, content=谢谢梅斯分享这么多精彩信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anti-cancer, createdTime=Sun May 10 14:10:43 CST 2020, time=2020-05-10, status=1, ipAttribution=)]
    2020-05-10 旺医

    顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1865832, encodeId=723b1865832a7, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sat Mar 20 14:10:43 CST 2021, time=2021-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1983981, encodeId=0143198398102, content=<a href='/topic/show?id=b53b5984ec1' target=_blank style='color:#2F92EE;'>#晚期癌症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59847, encryptionId=b53b5984ec1, topicName=晚期癌症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ba58436, createdName=马龙, createdTime=Sat Jan 23 05:10:43 CST 2021, time=2021-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1674474, encodeId=c32316e4474e1, content=<a href='/topic/show?id=e8aa13359b1' target=_blank style='color:#2F92EE;'>#Oncology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13359, encryptionId=e8aa13359b1, topicName=Oncology)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb7226973259, createdName=circumcision, createdTime=Sat Nov 28 06:10:43 CST 2020, time=2020-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289676, encodeId=92d512896e6e7, content=<a href='/topic/show?id=cbb8e1356f7' target=_blank style='color:#2F92EE;'>#癌症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71356, encryptionId=cbb8e1356f7, topicName=癌症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ba218, createdName=zgwhgch, createdTime=Tue May 12 02:10:43 CST 2020, time=2020-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1396587, encodeId=9c41139658e81, content=<a href='/topic/show?id=3497528842b' target=_blank style='color:#2F92EE;'>#恶心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52884, encryptionId=3497528842b, topicName=恶心)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Tue May 12 02:10:43 CST 2020, time=2020-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036085, encodeId=d3e31036085a4, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Sun May 10 14:10:43 CST 2020, time=2020-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1038032, encodeId=2daa103803215, content=谢谢梅斯分享这么多精彩信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anti-cancer, createdTime=Sun May 10 14:10:43 CST 2020, time=2020-05-10, status=1, ipAttribution=)]
    2020-05-10 anti-cancer

    谢谢梅斯分享这么多精彩信息

    0

相关资讯

Intern Med J:晚期癌症患者生命最后30天 如何选择治疗?

近年来,可用的癌症治疗方法出现显着性增多。但是,个别患者中,停止积极治疗的最合适时机的选择仍然困难。2017年3月,发表在《Intern Med J.》的一项研究对此进行分析。目的:旨在确定在生命的最后30天接受全身抗癌治疗的患者中正在接受姑息治疗的比例。方法:这是在卡布里尼医院的墨尔本肿瘤学组进行的一项回顾性队列研究。研究纳入了2014年1月1日~2014年6月30日死亡的姑息治疗管理的患者。结

临床试验表明:免疫治疗可以提高肺癌患者的生存率

根据一项新的研究报告,针对晚期肺癌患者的III期临床试验的结果可以帮助肿瘤学家更好地预测哪些患者可能从免疫治疗中获益最多,作为基于其肿瘤独特分子特征的一线治疗。

疟原虫治疗晚期癌症获初步疗效

利用疟原虫感染,启动人体抗肿瘤天然和适应性免疫应答,抑制肿瘤血管生成,抑制肿瘤的生长和转移……这些对晚期癌症的初步临床疗效成果,在10月19日上午举行的“2017疟疾与癌症跨界交流会”,得到了与会专家的高度关注。

疟原虫治晚期癌症志愿者招募已满:疗法处早期阶段,理性就医

春节刷屏至今的“疟原虫治疗晚期癌症”项目有了新的动态,该项目由中科院广州生物医药与健康研究院研究员陈小平主导。2月14日,记者在广州中科蓝华生物科技有限公司(下称“中科蓝华”)官网看到,网站发布一则通知:疟原虫免疫疗法治疗晚期癌症临床研究招募志愿者名额已满。中国临床试验注册中心官网显示,中科蓝华为三项疟原虫治疗癌症相关项目的申请人所在单位、研究实施负责单位。该公司成立于2013年1月,注册资本19

曾仕强教授患癌逝世 晚期癌症治还是不治?

日前,中国台湾著名学者曾仕强因癌症去世。曾仕强教授在被发现有癌症大概是在2016年9月份,但那时候癌症发展到了四期,癌细胞也广泛扩散到了身体各个部位,也因此错过了开刀的时间,但他也没做化疗,而是选择了放射性治疗,经过一段时间发现不疼了后,却又停止了!称要与癌细胞共存活。在其后仅服用中药与靠着自己的理念让癌细胞不在疼痛,直到在2年后的今年11月11日与世长辞,享年84岁。

Eur J Intern Med:大麻改善晚期癌症患者生存质量:真相究竟是什么?

2018年3月《European Journal of Internal Medicine》欧洲内科医学杂志最新发表的文章“大型前瞻性研究——医用大麻在癌症人群中的安全性和疗效” ,首次证实了几十年来关于大麻在癌症患者中的获益,大麻对癌症患者可能是安全有效的姑息治疗。

拓展阅读

【协和医学杂志】《晚期癌症患者呼吸困难处理:美国临床肿瘤学会指南》解读

本文对该指南重点内容进行详细解读,并结合中国国情进行分析,以期为指导中国临床实践提供参考。

严颖:晚期乳腺癌抗HER2合理分层治疗

抗HER2靶向治疗药物分层 抗HER2靶向治疗药物根据药物作用机制可以分为两大类:一类是单克隆抗体类,其中包括曲妥珠单抗等;另一类是小分子酪氨酸激酶抑制剂,包括拉帕替尼等。

Nat Cancer:基因检测公司Natera的Signatera ctDNA测试显示出晚期癌症的免疫疗法反应预测能力

导言:Natera作为全球领先的基因检测公司,在产前及肿瘤基因检测领域拥有深厚的技术背景及商业化经验。该公司的Signatera方法不同于目前可用的液体活检方法,它能够为每位患者提供量身定制的血液检测

疟原虫治晚期癌症志愿者招募已满:疗法处早期阶段,理性就医

春节刷屏至今的“疟原虫治疗晚期癌症”项目有了新的动态,该项目由中科院广州生物医药与健康研究院研究员陈小平主导。2月14日,记者在广州中科蓝华生物科技有限公司(下称“中科蓝华”)官网看到,网站发布一则通知:疟原虫免疫疗法治疗晚期癌症临床研究招募志愿者名额已满。中国临床试验注册中心官网显示,中科蓝华为三项疟原虫治疗癌症相关项目的申请人所在单位、研究实施负责单位。该公司成立于2013年1月,注册资本19

曾仕强教授患癌逝世 晚期癌症治还是不治?

日前,中国台湾著名学者曾仕强因癌症去世。曾仕强教授在被发现有癌症大概是在2016年9月份,但那时候癌症发展到了四期,癌细胞也广泛扩散到了身体各个部位,也因此错过了开刀的时间,但他也没做化疗,而是选择了放射性治疗,经过一段时间发现不疼了后,却又停止了!称要与癌细胞共存活。在其后仅服用中药与靠着自己的理念让癌细胞不在疼痛,直到在2年后的今年11月11日与世长辞,享年84岁。